Literature DB >> 9185104

Pathogenesis of water and sodium retention in cirrhosis.

P Y Martin1, R W Schrier.   

Abstract

The pathogenesis of renal sodium and water retention in cirrhosis involves extrarenal mechanisms because when kidneys from cirrhotic patients are transplanted into persons with normal livers, renal sodium and water retention no longer occurs. Cirrhosis is accompanied by portal hypertension, which leads to a hyperdynamic circulatory state. The Peripheral Arterial Vasodilation Hypothesis incriminates a relative underfilling of the arterial vascular compartment, which leads to the same neurohumoral responses that occurs in low cardiac output. Activation of the renain-angiotensin-aldosterone axis and the sympathetic system as well as non-osmotic release of vasopressin are well documented in cirrhosis. This sequence of events results in renal water and sodium retention, failure to escape from the sodium-retaining effect of aldosterone, and renal resistance to atrial natriuretic peptide. Dilutional hyponatremia is the strongest predictor of the occurrence of hepatorenal syndrome. The pathogenesis of the peripheral arterial vasodilation is not completely elucidated, but there is evidence for a major role of nitric oxide (NO). Increased vascular NO production has been demonstrated in cirrhosis. In the rat model of cirrhosis, normalization of vascular NO production with a NOS inhibitor corrects the hyperdynamic circulation, improves sodium and water excretion, and decreases neurohumoral activation. This insight into the mechanism(s) of the peripheral arterial vasodilation in cirrhosis should provide new tools in the treatment of edema and ascites, a major cause of morbidity and mortality in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185104

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  7 in total

1.  High Output Cardiac Failure.

Authors:  Inder S. Anand; Viorel G. Florea
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-04

2.  Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia.

Authors:  T P Nedungadi; F R Carreño; J D Walch; C S Bathina; J T Cunningham
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

3.  Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic rats.

Authors:  Flávia Regina Carreño; Lisa L Ji; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-12-17       Impact factor: 3.619

4.  An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.

Authors:  Werner G Purschke; Dirk Eulberg; Klaus Buchner; Stefan Vonhoff; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

5.  The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.

Authors:  Jun Jae Kim; Jeong Han Kim; Ja Kyung Koo; Yun Jung Choi; Soon Young Ko; Won Hyeok Choe; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2014-03-26

6.  Symptomatic hyponatremia: a rare but reversible adverse reaction of lubiprostone.

Authors:  Tsuneo Takenaka; Mikio Zeniya; Soichiro Miura; Takahiro Amano
Journal:  BMJ Case Rep       Date:  2020-03-17

7.  Hyponatremia-induced osteoporosis.

Authors:  Joseph G Verbalis; Julianna Barsony; Yoshihisa Sugimura; Ying Tian; Douglas J Adams; Elizabeth A Carter; Helaine E Resnick
Journal:  J Bone Miner Res       Date:  2010-03       Impact factor: 6.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.